Clinical Trial Update: A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the drug-drug interaction between cabozantinib (XL184) and rosiglitazone in subjects with solid tumors; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Carcinoma
• Hurthle Cell Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Rosiglitazone (rosiglitazone)
• cabozantinib (XL184) (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Papillary Thyroid Cancer, Follicular Thyroid Cancer | Phase 1 | Status: COMPLETED